July/August 2018

Column

Editor's Page

Balancing Costs and Patient Safety When Navigating New Regulations

08/22/2018

Winston Wong, PharmD, Editor-in-Chief

As new and exciting advancements in cancer drugs and care are made, updated guidance and regulations must follow. Oncologists and other stakeholders must keep up with the latest rules and regulations in order to...

As new...

08/22/2018

Journal of Clinical Pathways

PATIENT PERSPECTIVE

Talking About Costs of Care During Shared Decision Making—Part One: The Problem

08/22/2018

Alan Balch, PhD—Column Editor

In Part 1 of this 2-part column series on shared decision making, we discuss the need for health care teams to create a safe and inviting environment for patients to talk about financial concerns and questions...

In...

08/22/2018

Journal of Clinical Pathways

Clinical Pathways GPS

Communicating More Through Clinical Pathways to Advance Value-Based Health Care

08/22/2018

Richard G Stefanacci, DO, MGH, MBA, AGSF, CMD—Column Editor

The Food and Drug Administration (FDA) recently published guidance that clarifies how pharmaceutical manufacturers can share product information with payers while remaining compliant with FDA rules on...

The...

08/22/2018

Journal of Clinical Pathways

Counterpoint

CAR-T Therapies: Placing Patient Safety First

08/22/2018

Chadi Nabhan, MD, MBA, FACP

Bruce A Feinberg, DO

The commercial success and ability of eligible patients to receive chimeric antigen receptor T-cell (CAR-T) therapies depend on optimizing the logistics of delivering this transformational treatment platform. One...

The...

08/22/2018

Journal of Clinical Pathways

Viewpoint

CMS Sets CAR-T Reimbursement Levels—Where Should the Patient Be Treated?

08/22/2018

Winston Wong, PharmD, Editor-in-Chief

The Centers for Medicare and Medicaid Services (CMS) just announced their reimbursement level for the new chimeric antigen receptor T-cell (CAR-T) products. While it is in line with their standard reimbursement...

The...

08/22/2018

Journal of Clinical Pathways

News

Conference Coverage

ESMO World Congress on Gastrointestinal Cancer 2018

08/22/2018

JCP Editors

With over 18,000 members representing oncology professionals from over 150 countries, the European Society for Medical Oncology (ESMO) is the leading professional organization for medical oncology. ESMO’s educational...

With...

08/22/2018

Journal of Clinical Pathways

Insights

Interview

Wolters Kluwer Clinical Decision-Making Tool Offers Evidence-Backed Support

08/22/2018

JCP Editors

Wolters Kluwer recently launched UpToDate Advanced, a new evidenced-backed tool to help standardize clinical decisions and reduce costs. This new tool makes use of the UpToDate Pathways, which are built upon the...

...

08/22/2018

Journal of Clinical Pathways

Feature

Research Reports

KRAS/RAS Testing Is Associated With Reduced Risk of Treatment Discontinuation in Patients With Metastatic Colorectal Cancer

08/22/2018

Alexandra Christodoulopoulou, MSc

Bruce A Bach, MD, PhD

Andrew J Klink, PhD, MPH

Guy Hechmati, MD, MSc

Urvi Mujumdar, MPH

Bruce A Feinberg, DO

Marwan Fakih, MD

Abstract: Current clinical guidelines recommend that all patients with metastatic colorectal cancer (mCRC) have tumor tissue genotyped for RAS mutations. This study aimed to evaluate patient characteristics and...

...

08/22/2018

Journal of Clinical Pathways

Current Issue

June 2024

Volume 10

Issue 3

Current Issue

Issue Archive

Special Reports

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Winston Wong, PharmD

Gordon Kuntz

Robin T Zon, MD, FACP, FASCO

2021 Care Pathways Working Group

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

$Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma$

Special Report

Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma

01/14/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Editorial Correspondence

July/August 2018

Column

News

Insights

Feature

Current Issue

Special Reports

Subscribe

Volume 4

Specialties

Events

Year Round Education

HMP Global Products